Zuellig Pharma Corporation

Zuellig Pharma Corporation, a Pharmaceutical Preparation Manufacturing company headquartered in the Philippines, reported its 2021 Scope 3 carbon emissions at approximately 182,171,000 kg CO2e. This figure includes significant contributions from upstream transportation and distribution (approximately 108,342,000 kg CO2e), fuel and energy-related activities (approximately 14,692,000 kg CO2e), and purchased goods and services (approximately 17,332,000 kg CO2e). Specific data for Scope 1 and Scope 2 emissions for 2021 were not provided.

Zuellig Pharma Corporation is committed to ambitious climate action, with Science Based Targets initiative (SBTi) validated targets. The company aims to achieve net-zero greenhouse gas emissions across its value chain by 2045. As a near-term goal, Zuellig Pharma has committed to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030, using a 2021 base year. Additionally, the company plans to reduce absolute Scope 3 GHG emissions from fuel and energy-related activities, upstream transportation and distribution, and waste generated in operations by 25% within the same timeframe. For the long term, Zuellig Pharma commits to a 90% reduction in absolute Scope 1 and 2 GHG emissions by 2045 from a 2021 base year. Concurrently, it aims to reduce absolute Scope 3 emissions from purchased goods and services, capital goods, fuel- and energy-related activities, upstream transportation and distribution, and waste generated from operations by 90% by 2045. These targets are consistent with reductions required to keep warming to 1.5°C. The company also states a public commitment to be carbon neutral for its own operations by 2030, with a mid-term 35% reduction target by 2025. These targets and commitments are directly from Zuellig Pharma Corporation.